Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 20% if they invested a year ago

Bristol-Myers Squibb Co's Dividend Analysis

Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know

Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

US takes next step in Medicare drug price negotiations with pharma companies

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study

Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024

Income Investors Should Know That Bristol-Myers Squibb Company (NYSE:BMY) Goes Ex-Dividend Soon

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Bristol Myers Squibb (NYSE:BMY) Slips after Disappointing Drug Trial

Bristol Myers' bowel disease drug fails to meet main goal in late-stage study

UPDATE 2-Bristol Myers' bowel disease drug fails in late-stage study

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease